Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 810-816

  Sebolt Leopold, Judith S ^a   Dudley, David T ^a   Herrera, Roman ^a   Van Becelaere, Keri ^a   Wiland, Amy ^a   Gowan, Richard C ^a   Tecle, Haile ^b   Barret, Stephen D ^b   Bridges, Alexander ^b   Przybranowski, Sally ^c   Leopold, W R ^c   Saltiel, Alan R ^a  

^a Department of Cell Biology ^*  (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; COLON TUMOR; DRUG EFFICACY; DRUG MECHANISM; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; BENZAMIDES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CADHERINS; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032984348     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10533     Document Type: Article

References (37)

1. Lewis, T.S., Shapiro, P.S. & Ahn, N.C. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139 (1998).
2. Cobb, M.H. & Goldsmith, E.J. How MAP kinases are regulated. J. Biol. Chem. 270, 14843-14846 (1995).
3. Warne, P.H., Viciana, P.R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352-355 (1993).
4. Dent, P. et al. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257, 1404-1407 (1992).
5. Crews, C.M., Alessandrini, A. & Erikson, R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258, 478-480 (1992).
6. Her, J.H. et al. Dual phosphorylation and autophosphorylation in mitogen-activated protein (MAP) kinase activation. Biochem. J. 296, 25-31 (1993).
7. Anderson, N.C., Maller, J.L., Tonks, N.K. & Sturgill, T.W. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343, 651-653 (1990).
8. Marais, R., Wynne, J. & Treisman, R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73, 381-393 (1993).
9. Pang, L., Sawada, T., Decker, S.J. & Saltiel, A.R. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270, 13585-13588 (1995).
10. Cowley, S., Paterson, H., Kemp, P. & Marshall, C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77, 841-852 (1994).
11. Seger, R. et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. 267, 14373-14381 (1992).
12. Mansour, S.J. et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970 (1994).
13. Dudley, D.T. & Saltiel, A.R. in Signal Transduction, Cell Cycle, and Their Inhibitors (ed. Gutkind, J.S.)(Humana, Totowa, New Jersey, in the press).
14. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
15. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. & Saltiel, A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
16. Pages, G. et al. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci USA 90, 8319-8323 (1993).
17. Streit, M., Schmidt, R., Hilgenfeld, R.U., Thiel, E. & Kreuser, E.D. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J. Mol. Med. 74, 253-268 (1996).
18. Ridley, A.J., Comoglio, P.M. & Hall, A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac and Rho in MDCK cells. Mol. Cell Biol. 15, 1110-1122 (1995).
19. Herrera, R. Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells. Involvement of the MAPK pathway. J. Cell Science 111, 1039-1049 (1998).
20. Potempa, S. & Ridley, A.J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185-2200 (1998).
21. Tanimura, S. et al. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 17, 57-65 (1998).
22. Webb, C.P., Van Aelst, L., Wigler, M.H. & Vande Woude, G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA 95, 8773-8778 (1998).
23. Khwaja, A., Lehmann, K., Marte, B.M. & Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273, 18793-18801 (1998).
24. Takahashi-Tezuka, M. et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol. Cell. Biol. 18, 4109-4117 (1998).
25. Weidner, K.M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173-176 (1996).
26. Klemke, R.L. et al. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137, 481-492 (1997).
27. Corbett, T.H., Griswold, D.P., Roberts, B.J., Peckham, J.C. & Schabel, F.M. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogen structure. Cancer Res. 35, 2434-2439 (1975).
28. Sivaraman, V.S., Wang, H., Nuovo, G.J. & Malbon, C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478-1483 (1997).
29. Mandell, J.W., Hussaini, I.M., Zecevic, M., Weber, M.J. & VandenBerg, S.R. In situ visualization of intratumor growth factor signaling. Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Amer. J. Pathol. 153, 1411-1423 (1998).
30. Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (1999).
31. Licato, L.L. et al. In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology 113, 1589-1598 (1997).
32. Licato, L.L. at Brenner. D.A. Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig. Dis. Sci. 43, 1454-1464 (1998).
33. Eliceiri, B.P., Klemke R., Stromblad, S. & Cheresh, D.A. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 140, 1255-1263 (1998).
34. Milanini, J., Vinals, F., Pouyssegur, J. & Pages, G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273, 18165-18172 (1998).
35. Petit, A.M. et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530 (1997).
36. Fiddes, R.J. et al. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene 16, 2803-2813 (1998).
37. Amundadottir, L.T. & Leder, P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16, 737-746 (1998).